Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Heron Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.30M, down 4.3% year over year. For fiscal 2025 it was $12.43M, down 25.5% from the year before. Over ten years it grew -14.7% a year on average. The highest annual figure on record is $174.53M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.43M | -25.5% |
| FY2024 | Dec 31, 2024 | $16.68M | -57.4% |
| FY2023 | Dec 31, 2023 | $39.13M | -52.7% |
| FY2022 | Dec 31, 2022 | $82.70M | -36.8% |
| FY2021 | Dec 31, 2021 | $130.82M | -25.0% |
| FY2020 | Dec 31, 2020 | $174.53M | +4.3% |
| FY2019 | Dec 31, 2019 | $167.38M | +19.5% |
| FY2018 | Dec 31, 2018 | $140.03M | +1.0% |
| FY2017 | Dec 31, 2017 | $138.58M | +34.4% |
| FY2016 | Dec 31, 2016 | $103.13M | +68.6% |
| FY2015 | Dec 31, 2015 | $61.18M | +11.6% |
| FY2014 | Dec 31, 2014 | $54.83M | +68.6% |
| FY2013 | Dec 31, 2013 | $32.52M | +114.3% |
| FY2012 | Dec 31, 2012 | $15.17M | +84.9% |
| FY2011 | Dec 31, 2011 | $8.21M | +13.0% |
| FY2010 | Dec 31, 2010 | $7.26M | -6.8% |
| FY2009 | Dec 31, 2009 | $7.80M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.70M | -7.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.39M | +4.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.75M | +17.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.47M | -22.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.93M | -33.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.28M | -50.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.18M | -59.3% |
| Q3 FY2024 | Sep 30, 2024 | $4.47M | -51.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.43M | -66.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.61M | -47.8% |
| Q4 FY2023 | Dec 31, 2023 | $7.80M | -29.4% |
| Q3 FY2023 | Sep 30, 2023 | $9.29M | -63.7% |
| Q2 FY2023 | Jun 30, 2023 | $13.21M | -54.2% |
| Q1 FY2023 | Mar 31, 2023 | $8.84M | -79.0% |
| Q4 FY2022 | Dec 31, 2022 | $11.06M | -61.7% |
| Q3 FY2022 | Sep 30, 2022 | $25.55M | -10.7% |
| Q2 FY2022 | Jun 30, 2022 | $28.83M | -18.2% |
| Q1 FY2022 | Mar 31, 2022 | $42.07M | +10.4% |
| Q4 FY2021 | Dec 31, 2021 | $28.88M | -35.0% |
| Q3 FY2021 | Sep 30, 2021 | $28.60M | -41.9% |
| Q2 FY2021 | Jun 30, 2021 | $35.23M | -19.9% |
| Q1 FY2021 | Mar 31, 2021 | $38.12M | +3.3% |
| Q4 FY2020 | Dec 31, 2020 | $44.45M | -7.9% |
| Q3 FY2020 | Sep 30, 2020 | $49.18M | +41.7% |
| Q2 FY2020 | Jun 30, 2020 | $44.00M | +6.2% |
| Q1 FY2020 | Mar 31, 2020 | $36.89M | -14.1% |
| Q4 FY2019 | Dec 31, 2019 | $48.28M | +21.0% |
| Q3 FY2019 | Sep 30, 2019 | $34.71M | +14.1% |
| Q2 FY2019 | Jun 30, 2019 | $41.43M | +37.4% |
| Q1 FY2019 | Mar 31, 2019 | $42.97M | +8.6% |
| Q4 FY2018 | Dec 31, 2018 | $39.89M | -16.5% |
| Q3 FY2018 | Sep 30, 2018 | $30.42M | +5.5% |
| Q2 FY2018 | Jun 30, 2018 | $30.16M | +5.5% |
| Q1 FY2018 | Mar 31, 2018 | $39.56M | +18.5% |
| Q4 FY2017 | Dec 31, 2017 | $47.76M | +61.9% |
| Q3 FY2017 | Sep 30, 2017 | $28.84M | -4.6% |
| Q2 FY2017 | Jun 30, 2017 | $28.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $33.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $29.51M | – |
| Q3 FY2016 | Sep 30, 2016 | $30.24M | – |
See a number that looks wrong?